Country: France
Language: English
Source: HMA (Heads of Medicines Agencies)
carbimazole 10 mg
Intervet Intenational BV
QH03BB01
Tablet
carbimazole
Cats
2011-10-26
Revised: January 2012 AN: 02006/2010 Page 1 of 8 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Vidalta 10 mg prolonged-release tablets for cats BE, NO: Vidalta Vet 10 mg prolonged-release tablets for cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each prolonged-release tablet contains: ACTIVE SUBSTANCE: Carbimazole 10.00 mg EXCIPIENTS: Red ferric oxide (E172) 0.25 mg For a full list of excipients, see section 6.1 3. PHARMACEUTICAL FORM Prolonged-release tablet Round pink tablet with little spots 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Cat 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Treatment of hyperthyroidism and hyperthyroidism-associated clinical signs in cats 4.3 CONTRAINDICATIONS Do not use in cats suffering from concurrent systemic diseases, such as severe primary liver disease or diabetes mellitus. Do not use in cats showing signs of auto-immune diseases and/or altered red or white blood cell counts, such as anaemia, neutropaenia or lymphopaenia. Revised: January 2012 AN: 02006/2010 Page 2 of 8 Do not use in cats with platelet disorders (particularly thrombocytopaenia) or coagulopathies. Do not use in cats with hypersensitivity to mercaptoimidazoles (carbimazole or thiamazole (methimazole)) Please refer to section 4.7. 4.4 SPECIAL WARNINGS FOR THE TARGET SPECIES Thiamazole (methimazole), the active metabolite of carbimazole, inhibits thyroid hormone production and therefore cessation of treatment with carbimazole will result in a r Read the complete document